You may be unsuitable for this slimming injection if you: Have any known allergies to ingredients in it Are breastfeeding, pregnant or planning to conceive Are over 75 years old or under 18 years Have severe heart failure Have diabetes and currently take other medications containing GLP-1 (lixisenatide or exenatide) or have hypoglycaemia (low blood sugar) Have severe gut or stomach problems like inflammatory bowel disease or gastroparesis (delayed stomach emptying) Have severe kidney or liver disease or on dialysis Ensure you mention to your weight loss doctor the following conditions: Pancreatic diseases Diabetes Gallstones or inflamed gallbladder A racing heart or heart palpitations Thyroid diseases, including enlargement of the thyroid gland and thyroid nodules Mild to moderate kidney or liver disease A condition requiring you to take anticoagulants such as warfarin Inflamed gallstones or gallbladder Included in our protocol, is screening for the above, so when you access our service, we will assess you to ensure safety of these medications

In large clinical trials, some people lost around 20 percent of their starting weight with tirzepatide
As a result of the trial, the Food and Drug Administration granted approval for the treatment in June 2021
Cox PH regression showed that compared with DPP-4i users, semaglutide users had a 46% lower risk of ischemic stroke (hazard ratio [HR], 0.54 [95% CI 0.410.72]), a 36% lower risk of MI (HR 0.64 [95% CI 0.490.84]), and a 41% lower risk of their composite (HR 0.59 [95% CI 0.490.72]
Semaglutide is typically injected once per week
Statistical analysis For this study, we employed one-way analysis of variance (ANOVA) and LSD to analyze normally distributed data and find statistically significant differences using GraphPad Prism, version 9.5.0